Bora Pharmaceutical Acquires US CDMO Business for NT$3.8 Billion, Expanding Large Molecule Contract Manufacturing Footprint
NQ Score
0/100
N1 Content Completeness
90
AI Summary (NQ-processed)
Bora Pharmaceutical announced its board approved the acquisition of the CDMO (Contract Development and Manufacturing Organization) business spun off from US biopharmaceutical company MacroGenics for a total transaction value of US$122.5 million (approximately NT$3.842 billion). This includes a large molecule production facility in Rockville, Maryland, and a warehouse center in Frederick, aiming to strengthen its global biopharmaceutical contract development and manufacturing presence.